Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: An open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers

Clinical Drug Investigation

Volumn 33, Issue 1, 2013, Pages 1-9

  Jiang, Tao ^a   Rong, Zhengxing ^a   Xu, Yiping ^a   Chen, Bing ^a   Xie, Yifan ^a   Chen, Congying ^a   Lu, Yang ^a   Shen, Yifeng ^a   Li, Huafang ^a   Sun, Jing ^a   Chen, Hongzhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; GENERIC DRUG; GENOMIC DNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHINA; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DNA SEQUENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAMPLING; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CROSS-OVER STUDIES; DRUGS, GENERIC; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHENOTYPE; SEROTONIN UPTAKE INHIBITORS; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84873044201     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0010-8     Document Type: Article

References (36)

1. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol. 1997;7(3):157-66.
2. Sundstro II, Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual dysphoric disorder. Acta Physiol Scand. 1999;167(2):A6-7.
3. Schaller JL, Behar D. Brief report: citalopram in child and adolescent depression with anxiety. Med Gen Med. 2001;3(5):1.
4. Prince JB, Bostic JQ, Monuteaux M, et al. Citalopram for the treatment of adolescent anxiety disorders: a pilot study. Psychopharmacol Bull. 2002 Summer;36(3):100-7.
5. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715-20.
6. Overo KF. Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol. 1978;14(1):69-73.
7. Fredricson Overo K. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):311-8.
8. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11(Suppl. 1):5-11.
9. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11-28.
10. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993;15(1):11-7.
11. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 1997;7(1):1-10.
12. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997;280(2):927-33.
13. Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31(10):1255-9.
14. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. British J Clin Pharmacol. 2003;56(4):415-21.
15. Gutierrez MM, Abramowitz W. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Clin Ther. 2000;22(12):1525-32.
16. Mendoza L, Hajduch M, Kekulova H, et al. Bioequivalence of two brands of citalopram 40 mg tablets after single oral administration to healthy volunteers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149(1):169-72.
17. Gschwend MH, Richter J, Sennewald R, et al. Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. Arzneimittelforschung. 2005;55(12):730-7.
18. Van Ameringen M, Mancini C, Patterson B, et al. Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. J Psychopharmacol. 2007;21(5):472-6.
19. Al-Ghazawi M, Tutunji M, Mohsen M, et al. Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. Int J Clin Pharmacol Ther. 2007;45(5):300-6.
20. Fudio S, Borobia AM, Pinana E, et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol. 2010;626(2-3):200-4.
21. Ruan ZR, Cheng YS, Zhou JF, et al. Genetic polymorphism of 4′-hydroxylation of S-mephenytoin in 148 Chinese of Han nationality. Zhongguo Yao Li Xue Bao. 1996;17(2):119-21.
22. Edeki TI, Goldstein JA, de Morais SM, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics. 1996;6(4):357-60.
23. Daniel HI, Edeki TI. Genetic polymorphism of S-mephenytoin 4′-hydroxylation. Psychopharmacol Bull. 1996;32(2):219-30.
24. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol. 1999;48(3):402-8.
25. Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 2000;66(14):PL175-81.
26. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15(1):124-9.
27. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001;47(1):45-50.
28. State Food and Drug Administration (SFDA), Center for Drug Evaluation. Guideline for bioavailability and bioequivalence studies of generic drug products [in Chinese; online]. Available from URL: http://www.cde.org.cn/zdyz. do?method=largePage&id=2066 [Accessed 2010 Jul 7].
29. State Food and Drug Administration (SFDA) of China. Guideline for Good Clinical Principles [in Chinese; online]. Available from URL: http://www.sda.gov.cn/WS01/CL0053/24473.html [Accessed 2010 Jul 7].
30. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996;272:210-8.
31. Ferguson RJ, De Morais SM, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998;284(1):356-61.
32. Jiang T, Rong Z, Peng L, et al. Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(5-6):615-9.
33. Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001;36(10):669-72.
34. Chen LL, Qin SY, Xie J, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 2008;9(6):691-702.
35. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989;46(2):198-207.
36. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP4502C19. Psychosomatics. 2006;47(1):75-85.